These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36214301)

  • 1. Cell Adhesion Molecule CD99 in Cancer Immunotherapy.
    Yu F; Liu G; Zhang H; Wang X; Wu Z; Xu Q; Wu Y; Chen D
    Curr Mol Med; 2023; 23(10):1028-1036. PubMed ID: 36214301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
    Kang LC; Dunphy CH
    Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse CD99 participates in T-cell recruitment into inflamed skin.
    Bixel G; Kloep S; Butz S; Petri B; Engelhardt B; Vestweber D
    Blood; 2004 Nov; 104(10):3205-13. PubMed ID: 15280198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
    Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
    Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD99 monoclonal antibody induce homotypic adhesion of Jurkat cells through protein tyrosine kinase and protein kinase C-dependent pathway.
    Kasinrerk W; Tokrasinwit N; Moonsom S; Stockinger H
    Immunol Lett; 2000 Jan; 71(1):33-41. PubMed ID: 10709783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability.
    Balaraman K; Deniz E; Nelson E; Pilicer SL; Atasoy S; Molotkova A; Sevim H; Tiwari PB; Üren A; Wolf C
    Eur J Med Chem; 2023 May; 251():115244. PubMed ID: 36917882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors.
    Husak Z; Printz D; Schumich A; Pötschger U; Dworzak MN
    J Leukoc Biol; 2010 Aug; 88(2):405-12. PubMed ID: 20453109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.
    Rocchi A; Manara MC; Sciandra M; Zambelli D; Nardi F; Nicoletti G; Garofalo C; Meschini S; Astolfi A; Colombo MP; Lessnick SL; Picci P; Scotlandi K
    J Clin Invest; 2010 Mar; 120(3):668-80. PubMed ID: 20197622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation.
    De Feo A; Sciandra M; Ferracin M; Felicetti F; Astolfi A; Pignochino Y; Picci P; Carè A; Scotlandi K
    Cell Death Dis; 2019 Jun; 10(7):471. PubMed ID: 31209202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity.
    Husak Z; Dworzak MN
    Cell Death Dis; 2012 Nov; 3(11):e425. PubMed ID: 23152061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
    Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
    J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.
    O'Neill AF; Dearling JL; Wang Y; Tupper T; Sun Y; Aster JC; Calicchio ML; Perez-Atayde AR; Packard AB; Kung AL
    Clin Cancer Res; 2014 Feb; 20(3):678-87. PubMed ID: 24218512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing's sarcoma tumor cells.
    Gellini M; Ascione A; Flego M; Mallano A; Dupuis ML; Zamboni S; Terrinoni M; D'Alessio V; Manara MC; Scotlandi K; Picci P; Cianfriglia M
    Curr Pharm Biotechnol; 2013; 14(4):449-63. PubMed ID: 22335486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD99 expressed on human mobilized peripheral blood CD34+ cells is involved in transendothelial migration.
    Imbert AM; Belaaloui G; Bardin F; Tonnelle C; Lopez M; Chabannon C
    Blood; 2006 Oct; 108(8):2578-86. PubMed ID: 16825498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gingipains of Porphyromonas gingivalis modulate leukocyte adhesion molecule expression induced in human endothelial cells by ligation of CD99.
    Yun PL; Decarlo AA; Hunter N
    Infect Immun; 2006 Mar; 74(3):1661-72. PubMed ID: 16495537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD99 is a key mediator of the transendothelial migration of neutrophils.
    Lou O; Alcaide P; Luscinskas FW; Muller WA
    J Immunol; 2007 Jan; 178(2):1136-43. PubMed ID: 17202377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triggering of CD99 on monocytes by a specific monoclonal antibody regulates T cell activation.
    Laopajon W; Pata S; Takheaw N; Surinkaew S; Khummuang S; Kasinrerk W
    Cell Immunol; 2019 Jan; 335():51-58. PubMed ID: 30396687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD99 acts as an oncosuppressor in osteosarcoma.
    Manara MC; Bernard G; Lollini PL; Nanni P; Zuntini M; Landuzzi L; Benini S; Lattanzi G; Sciandra M; Serra M; Colombo MP; Bernard A; Picci P; Scotlandi K
    Mol Biol Cell; 2006 Apr; 17(4):1910-21. PubMed ID: 16421247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
    Tavakkoli M; Chung SS; Park CY
    Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Tumor Vascular CD99 Inhibits Tumor Growth.
    Huijbers EJM; van der Werf IM; Faber LD; Sialino LD; van der Laan P; Holland HA; Cimpean AM; Thijssen VLJL; van Beijnum JR; Griffioen AW
    Front Immunol; 2019; 10():651. PubMed ID: 31001265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.